Senzime’s Year-end Bulletin 2018
Financial information fourth quarter 2018
- Net sales amounts to KSEK 2,671 (15)
- Income after financial items amounts to KSEK -11,288 (-3,671).
- Earnings per share before dilution amounts to SEK -0.23 (-0.09).
Financial information January - December 2018
- Net sales amounts to KSEK 3,214 (189)
- Income after financial items amounts to KSEK -26,763 (-13,027).
- Earnings per share before dilution amounts to SEK -0.58 (-0.33).
- The Board of directors proposes that no dividend be paid for the financial year.
Senzime has started the rollout of TetraGraph during 2018. A new important chapter in the company's history has begun. At the same time, we have just started the journey towards achieving our ambition to become a world leader in patient monitoring.
After a development and registration period we now begin a new phase where commercial focus and patient needs will be central. Surgeons, anesthetists and healthcare professionals all around the world needs to be able to more easily monitor patients before, during and after surgery. We can offer them solutions for high quality follow-up and monitoring that enables patients to recover faster and more safely.
TetraGraph's launch was initiated through several distribution and licensing agreements. Now we need a focused and proactive commercial support to our existing partnerships, key- and new markets to increase our sales. This is our priority for 2019.
In 2018, we also gained confidence from new institutional owners who provided capital for our commercialization and growth phase. Senzime has a good starting position and I look forward to leading the company's continued development.
Uppsala in February 2019, Pia Renaudin, CEO of Senzime AB (publ)
For further information, please contact:
Jessica Roxhed, CFO
Tel: +46 703-94 94 98, e-mail: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA, +46(0)8-528 00 399 is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 15th 2019, 08:45.